ÂÜŔňÂŇÂ×

Rhonda Rhyne has spent the past 20 years in executive management for biotechnology and medical technology companies. She has served as Chief Executive Officer, Chief Translational Officer, and Board Director for Prevencio since August 2013. Previously, she served as Chief Operating Officer and then President of CardioDynamics, a publicly-traded, innovative cardiovascular medical device company from 1996 to 2009. The company was sold to Sonosite, Inc. (now Fujifilm Holdings Corp., OTCPK: FUJIY) in August 2009.

Ms. Rhyne served as Chief Executive Officer and Board Director for Culture Technology, Inc., a privately-held biotechnology company specializing in growing skin for severely burned patients from 1992 to 1995.

Ms. Rhyne also founded Rhyne Life Sciences Consulting, a consultancy practice focused on emerging life science technologies.

She has received numerous awards including Ernst & Young’s Entrepreneur of the Year for Medical Products; Deloitte’s Technology Fast 50 award for the 50 fastest-growing technology and life science companies in Southern California for successive nine years; San Diego Business Journal’s Women Who Mean Business award; and Athena’s Pinnacle award for supporting women in bioscience business.

Ms. Rhyne has an MBA from The Anderson School of Management at the University of California at Los Angeles (UCLA) and a Bachelor of Pharmacy from Washington State University.